KRAS
A gene frequently mutated in cancers; long considered 'undruggable' until recent targeted therapies.
Coverage of KRAS is holding steady : 10 signals on the latest tracked day, down 17% from its three-week baseline of 12, across 3 domains (unchanged from a week ago). That makes it the #13 most-covered of the 348 concerns we track.
What’s changed
- HUTCHMED Enters Exclusive Global License Agreement with GSK for HMPL-A830, First-in-Class KRAS-EGFR ATTC - Quiver Quantitative · KRAS Mutation Research (Google News) · 2026-09-03
- New class of KRAS inhibitors shows promise in shrinking NF1 nerve tumors - Medical Xpress · KRAS Mutation Research (Google News) · 2026-09-02
- New class of KRAS Inhibitors Shows Promise at Shrinking NF1 Nerve Tumors - Research Horizons · KRAS Mutation Research (Google News) · 2026-09-02
- Synergy of KRAS-inhibitor Daraxonrasib Combined With Recombinant Methioninase on Pancreatic-cancer Cells But Not Normal Cells. · Anticancer Res · 2026-09-01
- Emerging Therapeutic Strategies for Non-G12C KRAS Mutations in Colorectal Cancer: Focusing on G12D and G12V. · J Gastrointest Cancer · 2026-09-01
- Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-09-01
What the reporting says
It shows up alongside Colorectal Cancer (109), Lung Cancer (66 — acquisition ×3), G12d (60), Pancreatic Cancer (49), KRAS Mutant (46), Egfr (27 — acquisition ×2), Immunotherapy (22), Pdac (19).
Two steps out: ctDNA (through Colorectal Cancer, 107 shared stories on the weaker link); Braf (through Colorectal Cancer, 75 shared stories on the weaker link); Wang (through Colorectal Cancer, 59 shared stories on the weaker link); MSI-H (through Colorectal Cancer, 57 shared stories on the weaker link).
Tracked since Jan 1, with coverage on 139 separate days — concentrated in Oncology and Pubmed Targeted.